PKM and cancer: This observation is often explained by cancer specific activation of multiple oncogenic signaling pathways, such as SRC [94], KRAS-MEK [81,82], and H-RAS [95], as well as overexpression of molecular players involved in membrane fusion machinery, such as PKM2 [96], also play a key role in the positive modulation of EV release.